BioBlocks, Full Spectrum to develop new small molecule therapeutics
As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and BioBlocks’ fragment based drug discovery platform technology,Fragment-to-Lead, will be combined. The technologies will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.